Evidence map›Paper›PMID 37426134›Full record

ArticleJournal of thoracic disease2023

Development of prognostic models to estimate the probability of lung injury one year after COVID-19-related hospitalization-a prospective study.

Ana Casal-Mouriño, José Manuel Álvarez-Dobaño, María Jesús Domínguez, Francisco Gude, María E Toubes, Óscar Lado-Baleato, Anxo Martínez de Alegría, Manuel Taboada, Vanessa Riveiro, Nuria Rodríguez-Núñez and 6 more

Abstract read
In one paragraph

Article in Journal of thoracic disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ana Casal-MouriñoPulmonology Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain.
José Manuel Álvarez-DobañoPulmonology Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain.
María Jesús DomínguezInternal Medicine Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain.
Francisco GudeClinical Epidemiology Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain.
María E ToubesPulmonology Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain.
Óscar Lado-BaleatoResearch Methods Group (RESMET), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
Anxo Martínez de AlegríaRadiology Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain.
Manuel TaboadaAnesthesia and Resuscitation Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain.
Vanessa RiveiroPulmonology Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain.
Nuria Rodríguez-NúñezPulmonology Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain.
Adriana LamaPulmonology Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain.
Lucía FerreiroPulmonology Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain.
Borja OteroEsteve Teijin Company, Clinical University Hospital of Santiago, Santiago de Compostela, Spain.
Juan Suárez-AnteloPulmonology Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain.
Antonio Pose *Internal Medicine Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain.
Luis Valdés *Pulmonology Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Long-term effects of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection still under study. The objectives of this study were to identify persistent pulmonary lesions 1 year after coronavirus disease 2019 (COVID-19) hospitalization and assess whether it is possible to estimate the probability that a patient develops these complications in the future. Methods: A prospective study of ≥18 years old patients hospitalized for SARS-COV-2 infection who develop persistent respiratory symptoms, lung function abnormalities or have radiological findings 6-8 weeks after hospital discharge. Logistic regression models were used to identify prognostic factors associated with a higher risk of developing respiratory problems. Models performance was assessed in terms of calibration and discrimination. Results: A total of 233 patients [median age 66 years [interquartile range (IQR): 56, 74]; 138 (59.2%) male] were categorized into two groups based on whether they stayed in the critical care unit (79 cases) or not (154). At the end of follow-up, 179 patients (76.8%) developed persistent respiratory symptoms, and 22 patients (9.4%) showed radiological fibrotic lesions with pulmonary function abnormalities (post-COVID-19 fibrotic pulmonary lesions). Our prognostic models created to predict persistent respiratory symptoms [post-COVID-19 functional status at initial visit (the higher the score, the higher the risk), and history of bronchial asthma] and post-COVID-19 fibrotic pulmonary lesions [female; FVC% (the higher the FVC%, the lower the probability); and critical care unit stay] one year after infection showed good (AUC 0.857; 95% CI: 0.799-0.915) and excellent performance (AUC 0.901; 95% CI: 0.837-0.964), respectively. Conclusions: Constructed models show good performance in identifying patients at risk of developing lung injury one year after COVID-19-related hospitalization.

Indexed as

clinical prediction modelsfibrotic pulmonary lesionsPost-acute coronavirus disease 2019 syndrome (post-acute COVID-19 syndrome)radiological findingsrespiratory functional testrespiratory symptoms

Identifiers

PMID37426134
PMCPMC10323564

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.